Quiflox/Marfloquin 20 mg/ml solution for injection

Main information

  • Trade name:
  • Quiflox/Marfloquin 20 mg/ml solution for injection
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Quiflox/Marfloquin 20 mg/ml solution for injection
    Spain
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • marbofloxacin
  • Therapeutic area:
  • Cattle, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0223/001
  • Authorization date:
  • 23-02-2011
  • EU code:
  • FR/V/0223/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

1.3.1 Marbofloxacin

SPC,LabelingandPackageLeaflet FR

SmPCPIL013708/3 20.09.2010–Updated:10.02.2011 Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1.3.1 Marbofloxacin

SPC,LabelingandPackageLeaflet FR

SmPCPIL013708/3 20.09.2010–Updated:10.02.2011 Page2of6

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Quiflox20mg/mlsolutionforinjectionforcattle(calves)andpigs

Marfloquin20mg/mlsolutionforinjectionforcattle(calves)andpigs

Quiflox20mg/mlsolutionforinjectionforcattle(calves)andpigs(CzechRepublic,Hungary,Latvia,

Lithuania,SlovakRepublic)

Marfloquin20mg/mlsolutionforinjectionforcattle(calves)andpigs(Austria,Belgium,Denmark,

Finland,France,Germany,Greece,Italy,Luxembourg,Netherlands,Norway,Portugal,Spain,United

Kingdom)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

1mlofsolutionforinjectioncontains:

Activesubstance:

Marbofloxacin 20mg

Excipients:

Metacresol 2mg

Disodiumedetate 0.10mg

Monothioglycerol 0.50mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Clear,greenishyellowtobrownishyellowsolution.

4. CLINICALPARTICULARS

4.1Targetspecies

Cattle(calves).

Pigs.

4.2Indicationsforuse,specifyingthetargetspecies

Inpre-ruminantandruminantcalves:

- treatmentofrespiratoryinfectionscausedbysensitivestrainsofPasteurellamultocida,

Mannheimiahaemolytica,andMycoplasmabovis.

Inpigs:

- treatmentofrespiratoryinfectionscausedbysensitivestrainsofActinobacillus

pleuropneumoniae,Mycoplasmahyopneumoniae,andPasteurellamultocida.

Thisproductshouldonlybeusedbasedonsusceptibilitytesting.

4.3Contraindications

1.3.1 Marbofloxacin

SPC,LabelingandPackageLeaflet FR

SmPCPIL013708/3 20.09.2010–Updated:10.02.2011 Page3of6

Donotuseincaseofdisturbanceingrowthofcartilageand/orduringinjuryoflocomotionsystem

particularyonfunctionallyloadedjoints.

Donotadministerinanimalswithknownhypersensitivitytomarbofloxacinoranyotherquinoloneor

toanyoftheexcipients.

4.4 Specialwarningsforeachtargetspecies

None.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Officialandlocalantimicrobialpoliciesshouldbetakenintoaccountwhentheproductisused.

Fluoroquinoloneshouldbereservedforthetreatmentofclinicalconditionswhichhaveresponded

poorly,orareexpectedtorespondpoorly,tootherclassesofantimicrobials.

Wherepossible,fluoroquinolonesshouldbeusedbasedonsusceptibilitytesting.

UseoftheproductdeviatingfrominstructionsgivenintheSPCmayincreasetheprevalenceof

bacteriaresistanttofluoroquinolonesandmaydecreasetheeffectivenessoftreatmentwithother

quinolonesduetothepotentialforcrossresistance.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinalproductto

animals

Washhandsafteruse.

Peoplewithknownhypersensitivityto(fluoro)quinolonesshouldavoidcontactwiththeproduct.

Directcontactwithskinshouldbeavoidedtoreducetheriskofsensitisationandcontactdermatitis.

Incaseofcontactwithskinoreyes,rinsewithplentyofwater.

Careshouldbetakentoavoidaccidentalselfinjection.

Incaseofaccidentalselfinjection,seekamedicaladviceandshowthelabeltothedoctor.

Accidentalself-injectioncaninduceaslightirritation.

4.6 Adversereactions(frequencyandseriousness)

Administrationbythesubcutaneousroutemayinduceatransientoedema.Intramuscular

administrationmaycausepainandinflammatorylesionsattheinjectionsite.Theinflammatorylesions

persist6daysinpigsand12daysincalves.

4.7 Useduringpregnancy,lactationorlay

Studiesinlaboratoryanimals(rats,rabbits)didnotshowanyevidenceofateratogenic,embryotoxic

ormaternotoxiceffectassociatedwiththeuseofmarbofloxacin.

Theproductshouldbeusedaccordingtothebenefit/riskassessmentcarriedoutbytheveterinarian.

Seesection4.11forwithdrawalperiods.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9Amountstobeadministeredandadministrationroute

Pre-ruminantandruminantcalves:

1.3.1 Marbofloxacin

SPC,LabelingandPackageLeaflet FR

SmPCPIL013708/3 20.09.2010–Updated:10.02.2011 Page4of6

-Intramuscularorsubcutaneoususe:

2mgofmarbofloxacinperkgofbodyweightperday,i.e.1mlofsolutionper10kgofbodyweightin

asingledailyinjectionfor3to5days.Thefirstinjectionmayalsobegivenbytheintravenousroute.

Pigs:

-Intramuscularuse:

2mgofmarbofloxacinperkgofbodyweightperday,i.e.1mlofsolutionper10kgofbodyweightin

asingledailyinjectionfor3to5days.

Thedosevolumegivenatoneinjectionsiteshouldnotexceed6mlincalvesand3mlinpigs.

Thecapmaybesafelypuncturedupto20times.Inordertoreducetheriskofparticulate

contaminationoftheproduct,itisrecommendedthatadraw-offneedlebeusedtoreducethenumber

oftimestheseptumispunctured.Theusershouldchoosethemostappropriatevialsizeaccordingto

thetargetspeciestotreat.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Nosignofoverdosagehasbeenobservedwithmarbofloxacinafteradministrationof3timesthe

recommendeddose.

Overdosagesymptomsofmarbofloxacinareacuteneurologicaldisordersthatshouldbetreated

symptomatically.

4.11Withdrawalperiod(s)

Meatandoffal:

-pre-ruminantandruminantcalves:6days.

-pigs:4days.

Thisproductisnotauthorisedforuseinlactatinganimalsproducingmilkforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse,Fluoroquinolones,ATCvetcode:

QJ01MA93

5.1Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobialbelongingtothefluoroquinolonegroup.Itacts

byinhibitionofDNAgyraseandhasabroad-spectrumactivityagainstGram-positivebacteria

(especiallyStaphylococcus),andGram-negativebacteria(Escherichiacoli,Pasteurellamultocida,

MannheimiahaemolyticaandActinobacilluspleuropneumoniae,aswellasagainstmycoplasma

(MycoplasmabovisandMycoplasmahyopneumoniae).

CasesofresistancehavebeenobservedinStreptococcus.

StrainswithMIC≤1µg/mlaresensitivetomarbofloxacinwhereasstrainswithMIC≥4µg/mlare

resistanttomarbofloxacin.

Resistancetofluoroquinolonesoccursbychromosomalmutationwiththreemechanisms:decreaseof

thebacterialwallpermeability,expressionofeffluxpumpormutationofenzymesresponsiblefor

moleculebinding.

5.2 Pharmacokineticparticulars

1.3.1 Marbofloxacin

SPC,LabelingandPackageLeaflet FR

SmPCPIL013708/3 20.09.2010–Updated:10.02.2011 Page5of6

Followingsubcutaneousorintramuscularadministrationoftherecommendeddoseof2mg/kgin

cattleorpigs,marbofloxacinisrapidlyabsorbedandattainsitsmaximumplasmaconcentrationof

1.5µg/mlwithinlessthananhour.Itsbioavailabilityiscloseto100%.

Marbofloxacinisweaklyboundtoplasmaproteins(<10%inpigs,<30%incattle)andwidely

distributedthroughouttheorganism.Inthemajorityoftissues(liver,kidney,skin,lung,uterus),it

achievesahigherconcentrationthaninplasma.

Marbofloxaciniseliminatedslowlyinpre-ruminatingcalves(t

β=5-9h)andinpigs(t

β=8-10h),

butfasterinruminantcattle(t

β=4-7h)predominantlyintheactiveforminurineandfaeces.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Gluconolactone

Disodiumedetate

Mannitol

Metacresol

Monothioglycerol

Waterforinjections

6.2 Incompatibilities

Donotmixwithothermedicinalproducts.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years.

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days.

6.4.Specialprecautionsforstorage

Storeintheoriginalpackageinordertoprotectfromlight.

Donotfreeze.

6.5 Natureandcompositionofimmediatepackaging

Bottle(amberglassPh.Eur.typeII),bromobutylrubberstopper,aluminiumclosure:50mlsolution

forinjection,inabox.

Bottle(amberglassPh.Eur.typeII),bromobutylrubberstopper,aluminiumclosure:100mlsolution

forinjection,inabox.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts

Anyunusedproductorwastematerialshouldbedisposedofinaccordancewithnationalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

1.3.1 Marbofloxacin

SPC,LabelingandPackageLeaflet FR

SmPCPIL013708/3 20.09.2010–Updated:10.02.2011 Page6of6

KRKA,d.d.,Novomesto,Šmarješkacesta6,8501Novomesto,Slovenia

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

10.DATEOFREVISIONOFTHETEXT

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Veterinaryprescription.

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

20-11-2018

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

FDA - U.S. Food and Drug Administration

24-10-2018

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling all products lots manufactured from February 27, 2018 through July 20, 2018, as a precaution because they have the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

22-6-2018

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

FDA - U.S. Food and Drug Administration

2-5-2018

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

9-11-2011

Danish Pharmacovigilance Update, 20 October 2011

Danish Pharmacovigilance Update, 20 October 2011

In this edition of Danish Pharmacovigilance Update, you can read about: Use of medicines involving a risk of serious and life-threatening skin reactions, the European Medicines Agency to investigate the possible connection between orlistat and rare cases of severe liver toxicity, and the EMA’s review of peritoneal dialysis solutions from Baxter A/S.

Danish Medicines Agency

26-11-2018

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health technologies.

FDA - U.S. Food and Drug Administration

4-9-2018

Agenda:  Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda: Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda of CHMP written procedure*20-23 August 2018

Europe - EMA - European Medicines Agency

22-8-2018

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye:  http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz . pic.twitter.com/ecJErFeiSH

FDA - U.S. Food and Drug Administration

20-7-2018

Agenda:  Agenda - CAT agenda of the 18-20 July 2018 meeting

Agenda: Agenda - CAT agenda of the 18-20 July 2018 meeting

Committee for Advanced Therapies (CAT) agenda for the meeting on 18-20 July 2018

Europe - EMA - European Medicines Agency

29-6-2018

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit  https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFriday pic.twitter.com/JWK672XtdI

FDA - U.S. Food and Drug Administration